Search results
Results From The WOW.Com Content Network
340B DSH hospitals provide nearly twice as much care as non-340B hospitals – 41.9 percent versus 22.8 percent – to Medicaid beneficiaries and low-income Medicare patients. 340B hospitals provide 40 percent more uncompensated care as a percent of total patient care costs than non-340B hospitals – $24.6 billion to $17.5 billion.
The 340B Drug Pricing Program, administered by the Office of Pharmacy Affairs, resulted from enactment of Public Law 102-585, the Veterans Health Care Act of 1992, which is codified as Section 340B of the Public Health Service Act. Section 340B limits the cost of covered outpatient drugs to more than 18,000 eligible entities including ten types ...
The 340B drug pricing program, originally intended to help low-income and uninsured patients, has been exploited by special interests for profit, resulting in higher drug prices, taxes, and ...
A big problem with 340B or similar programs is that pharmacies and hospitals can choose to bill for the discounted drugs at full price, defeating the purpose of the program to control drug prices and maintain affordability for low-income patients.
The Affordable Care Act (ACA), formally known as the Patient Protection and Affordable Care Act (PPACA) and informally as Obamacare, is a landmark U.S. federal statute enacted by the 111th United States Congress and signed into law by President Barack Obama on March 23, 2010.
In 2018, HHS proposed a new rule that would reduce reimbursement rates for only 340B hospitals, but did not conduct a survey of hospital acquisition costs. In its final rule, HHS retained the approximately 106 percent reimbursement rate for non-340B hospitals, and established a 77.5 percent reimbursement rate for 340B hospitals.
The state report did not name the patient who died after the C-section at California Hospital Medical Center. Sign up for Essential California, your daily guide to news, views and life in the ...
The Patients Act 2009 (Preserving Access to Targeted, Individualized, and Effective New Treatments and Services) is a bill set before the United States Congress in June 2009 which has been proposed by Senators Kyl and McConnell.